
© Magnific
November 18, 2026
Moira Hammes
Fixed routines and well-meant advice don’t help everyone who struggles to sleep. Charité sleep specialist Dr. Theresa Toncar explains when insomnia becomes chronic – and how targeted treatment can help.
Sleep problems are widespread: according to the German Society for Sleep Research and Sleep Medicine (DGSM), around one third of the population in Germany suffers from sleep disorders. Approximately six to ten percent meet the criteria for chronic insomnia. At the same time, there is no shortage of aids and recommendations – from sleep-tracking apps and melatonin supplements to guides on the perfect evening routine.
People who regularly sleep poorly have often already tried a great deal. Yet fixed bedtimes, reduced screen time, or a sleep mask don't always deliver the rest they hope for. Many sufferers seek medical help late – or not at all. So when does poor sleep become insomnia that requires treatment, and what helps when the standard recommendations fall short?
In an interview with Premium Medical Circle, Dr. med. Theresa Toncar, senior physician at the Interdisciplinary Sleep Medicine Center at Charité, explains the distinction between occasional sleep problems and a sleep disorder that requires treatment.
A specialist in internal medicine and a sleep medicine physician and somnologist certified by the DGSM, she explains why sleep hygiene recommendations don't always help and can sometimes add to a patient's pressure. She also shares insights into the treatment of chronic insomnia and assesses the potential of new medications and approaches such as neurostimulation.
From what point do you at the Charité sleep clinic consider someone to have chronic insomnia, and when is poor sleep still a "normal" response to stress?
In simplified terms, we speak of chronic insomnia when the 3×3 rule is met: patients take more than 30 minutes to fall asleep or fall back asleep on at least three nights per week for at least three months, and thesleep disorder has an impact on their daytime wellbeing. Many people occasionally struggle to fall or stay asleep. However, once daytime functioning is affected or the disturbance occurs too frequently, it is time to seek medical help.
Where do you draw the line: when is sleep hygiene actually useful, and when can it become counterproductive?
Many patients with insomnia suffer from what is known as psychophysiological insomnia. They become trapped in a vicious cycle of sleep-inhibiting thoughts, heightened arousal, impaired daytime wellbeing, and unhelpful coping strategies such as daytime napping or spending too long in bed.
For these patients, cognitive behavioral therapy – including its sleep hygiene component – is beneficial.Sleep hygiene becomes counterproductive, in my view, when it is applied compulsively and puts patients under pressure. Pressure creates stress, and as soon as we are stressed, our sleep suffers.
Do you see patients who do everything "by the book" – cool room, darkness, no phone – and are still completely exhausted? What might be going wrong?
Working at a sleep medicine center, I see many patients in my day-to-day clinical practice who cannot sleep and are utterly exhausted despite following sleep hygiene measures or completing cognitive behavioral therapy. Nothing in life is perfect, and so we shouldn't try to do anything "perfectly" either. What I'm about to say is very simple, but extremely important: every person is different.
I encourage my patients to listen to themselves and notice what actually helps them. In my experience, that is often where things go wrong: patients do what the books say, what their doctors, family members, or friends have recommended – but they rarely stop to ask themselves what genuinely works for them and their sleep.
Charité has dedicated research projects on stepped pharmacological therapy for chronic insomnia, examining sleep quality and quality of life across various medications. What does a typical treatment pathway look like at Charité – from the initial consultation to the specific therapy?
We begin in the outpatient clinic by assessing whether there are any organic causes for the insomnia. These might include obstructivesleep apnea, restless legs syndrome, or thyroid dysfunction. We also discuss sleep hygiene measures with the patient and determine whether cognitive behavioral therapy might be appropriate.
For several years now, we have also been increasingly prescribing digital health applications – apps designed to support patients and provide them with information about sleep andinsomnia. In addition, we offer pharmacological support to help stabilize sleep.
What specifically does the stepped pharmacological therapy involve?
A range of medications is available to us for pharmacological therapy. Seven steps have been established, starting with herbal substances and progressing through prolonged-release melatonin,antidepressants, newer medications such as daridorexant, and up to benzodiazepine receptor agonists (Z-drugs). Patients remain at each step for four weeks. If the treatment is ineffective, they move up to the next step; if it helps, it is continued.
Benzodiazepines and Z-drugs are still used in clinical practice despite the risk of dependence and side effects. Which medication groups concern you most today, because they are being used for too long or used inappropriately in practice?
Benzodiazepines, without question.
Which new substances or concepts do you find exciting from a sleep medicine perspective, and where do you remain cautious?
Daridorexant was approved in Germany in April 2022. It is a dual orexin receptor antagonist (DORA): orexin promotes wakefulness, and unlike benzodiazepines or Z-drugs – which enhance the sleep-promoting substance GABA – DORAs work by blocking a wakefulness promoter. It is an entirely different mechanism of action, which is why I find it so exciting.
Another exciting development is the treatment of women with insomnia during menopause. Since April 2025, elinzanetant has been available by prescription in Germany for women with vasomotor symptoms: not only do these patients experience fewerhot flashes, they also sleep better.
Patients also frequently ask about cannabinoids. Here I am genuinely very cautious: the data so far are weak, and in my view the risks should not be dismissed.
Melatonin is widely seen as "mild," but there are ongoing discussions about its risks and data relating to heart health. How do you assess the debate around melatonin?
You are referring to the controversy sparked by an abstract presented at the American Heart Association meeting in November 2025. That abstract reported that people who takemelatonin are more likely to develop heart failure, require hospitalization, and die than people who do not use melatonin.
It is important to understand that the content of an abstract has not yet been through any quality review – that happens during the publication process. In May 2026, the study results were published after independent peer review.
The review found that the study participants who took melatonin already differed substantially at baseline from those who had not taken melatonin, and that these pre-existing differences accounted for the different disease outcomes.
If you could give patients with chronic insomnia three concrete pieces of advice, what would they be?
Where do you see the greatest advances in the treatment of insomnia over the next five to ten years: in psychotherapy, medications, or neurostimulation?
In my view, psychotherapy will become more accessible in the coming years through digitalization – and that in itself can already be counted as progress. On the medication front, I currently see no new active ingredient on the horizon, so major advances there seem unlikely. That leaves neurostimulation: forchronic pain, it is already in use. I can well imagine that the greatest advances over the next ten years will come from that direction.

Veneers promise flawless teeth – but not every treatment is as gentle as many people think. Dentist Dr. Oliver Brendel explains which risks are often underestimated, when he advises against a treatment and what really makes a beautiful smile.
Christine Bürg & Marianne Waldenfels

An interview with
Dr. med. dent. Oliver Brendel

Familiar names slip your mind, concentration fades, and everyday tasks feel increasingly draining. Hormonal changes may be behind this brain fog — often beginning before the final menstrual period. Endocrinologist Dr. Alexandra Schoeneich explains what happens in the brain and what role hormone replacement therapy can play.
Christine Bürg & Marianne Waldenfels

An interview with
Dr. med. Alexandra Schoeneich

Artificial intelligence, digital diagnostics, and new technologies are transforming medicine. At the Digital Health Summit 2026 in Munich, leading scientists, physicians, founders, and investors explored how to turn cutting-edge research into better patient care — and why collaboration among Munich's leading institutions is key to making it happen
PMC Redaktion

With
Univ.-Prof. Dr. med. Dominik Pförringer